Page last updated: 2024-11-12
deinoxanthin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
deinoxanthin: isolated from Deinococcus radiodurans; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16061289 |
| CHEBI ID | 80464 |
| MeSH ID | M0544462 |
Synonyms (4)
| Synonym |
|---|
| deinoxanthin |
| LMPR01070182 |
| CHEBI:80464 |
| (5r)-5-hydroxy-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e,19e,21e)-24-hydroxy-3,7,12,16,20,24-hexamethylpentacosa-1,3,5,7,9,11,13,15,17,19,21-undecaenyl]-2,4,4-trimethylcyclohex-2-en-1-one |
Research Excerpts
Overview
Deinoxanthin (DX) is a unique carotenoid synthesized by Deinococcus radiodurans. It is one of the most radioresistant organisms known.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Deinoxanthin (DX) is a unique carotenoid synthesized by Deinococcus radiodurans, one of the most radioresistant organisms known. " | ( Insight into the strong antioxidant activity of deinoxanthin, a unique carotenoid in Deinococcus radiodurans. Ji, HF, 2010) | 2.06 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Deinoxanthin treatment caused an increase in ROS in all tested cells, suggesting possible pro-oxidant activity of deinoxanthin." | ( Induction of apoptosis by deinoxanthin in human cancer cells. Choi, JI; Choi, YJ; Hur, JM; Jo, M; Kim, DH; Lim, S, 2014) | 1.42 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| xanthophyll | A subclass of carotenoids consisting of the oxygenated carotenes. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.99
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.99) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (6.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||